News
What's happening in Alzheimer's care, research funding, and treatment — summarized simply, each item linked to the original reporting.
Free to read, “May need a subscription” and “Archived copy”: what they mean
Whether an article is free to read is a guess, not a test of your access. Each item is one of three:
- No label: free to read (304 of 349). The publisher’s page marks it free, or the outlet publishes free to read: Medical Xpress, ScienceDaily, NIH (incl. NIA and PMC), Alzheimer's Association, Alzheimer's News Today, NPR, Alzheimer's Disease International, or a .gov site.
- May need a subscription (11 of 349). The publisher’s own page marks the article as not free to read, or — when the page says nothing — the outlet sells subscriptions: The New York Times, STAT, Scientific American, The Washington Post, The Wall Street Journal, Financial Times, The Economist, Bloomberg, The Atlantic, The New Yorker, Wired, Los Angeles Times, The Boston Globe, The Times, The Telegraph, New Scientist, Endpoints News, Science. Each badge says which.
- “Free to read? Not known” (34 of 349). The outlet is on neither list and its page said nothing. We do not call these paywalled.
Archived copy links go to a copy the Internet Archive (web.archive.org) saved, dated the day it was saved. We show one only where the Internet Archive reported a working saved copy when we checked; an archived copy of a subscription article sometimes shows only its opening. 265 of 349 items have one.
New Alzheimer's Association Report: Americans Care Deeply About Brain Health But Most Don't Know How to Maintain It
The 2026 Facts and Figures report found 7.4 million Americans living with clinical Alzheimer's dementia, $409 billion in projected 2026 care costs, and a 134% rise in Alzheimer's-related deaths since 2000, alongside survey findings that most Americans don't know concrete steps to protect brain health (only 14% had discussed it with a doctor).
Why it matters: Updates the national scale and cost of Alzheimer's disease for policymakers and funders, and highlights a public-education gap around modifiable brain-health behaviors like sleep, diet, and exercise.
Read at Alzheimer's Association → Archived copy (26 Jul 2026), Internet ArchiveAlzheimer's Association Statement on Oral Semaglutide Phase 3 Topline Data Release
Novo Nordisk's EVOKE and EVOKE+ Phase 3 trials of oral semaglutide in more than 3,800 people with early symptomatic Alzheimer's did not meet the primary endpoint of significantly slowing disease progression, despite improving some Alzheimer's-related biomarkers. Novo Nordisk ended its Alzheimer's trials for semaglutide, including the injectable version.
Why it matters: A high-profile failure for the theory that GLP-1 weight-loss drugs could treat Alzheimer's, dampening near-term hopes for repurposing this popular drug class for dementia.
Read at Alzheimer's Association → Archived copy (30 Jul 2026), Internet ArchiveFollow new items in a feed reader: Atom feed.